Composition:
Each Injection
contains:
Cefotaxime....................................................................750
mg
Sulbuactam.................................................................1500
mg
Indications:
Used in surgical
prophylaxis, meningitis, skin & soft tissue infections like
cellulitis, chronic suppurative bacterial otits media,
cholecystitis, sexually transmitted disease, Urinary tract
infections, infections in dialysis unit.
Description:
Cefotaxime sodium,
a parenteral cephalosporin antibiotic, exerts its bactericidal
action through inhibition of bacterial cell wall synthesis.
Chemical structure modifications have enabled this compound to be
resistant to the action of Richmond I, III, IV, and V beta-lactamase
enzymes.
Excellent activity
against many gram-negative bacilli, especially Enterobacteriaceae,
has been demonstrated. Antipseudomonal activity is generally poor,
however. Activity against gram-positive cocci, with the notable
exception of Streptococcus fecalis, is adequate. Anaerobic
activity is variable, particularly against Clostridia and
Bacteroides species. Acute, subacute, and chronic toxicity studies
in animals were generally unremarkable. No mutagenic effects or
reproductive toxicity have been noted in animals.
In man, cefotaxime
is desacetylated to a microbiologically active metabolite. Urinary
excretion is approximately 50-60% and 15-20% of a dose for the
parent compound and desacetyl metabolite, respectively. The
elimination half-life of cefotaxime is about one hour, with the
total body clearance being approximately twice that of the renal
clearance. Severe renal dysfunction causes a prolongation of the
elimination half-life of cefotaxime and particularly desacetyl
cefotaxime.
A relatively low
degree of protein binding in part attributes to a wide bodily
distribution of cefotaxime. Cefotaxime is effective in a variety
of infectious processes caused by susceptible organisms. Local
reactions at the injection site and hypersensitivity phenomena are
the most common adverse effects. Comparative trials attesting to
cefotaxime's clinical utility over other parenteral cephalosporins
or amino-glycosides are very limited. Based on the available
evidence, cefotaxime should be most useful in combating serious
gram-negative infections, because of its excellent activity
against most of these organisms and its low toxicity profile.
CONTRAINDICATIONS
Bactram
is contraindicated in patients who have shown
hypersensitivity to cefotaxime sodium or the cephalosporin group
of antibiotics.
Dosage:
As per the physician’s advice.
Presentations: |
Quality
